Chemiluminescence Immunoassay Market Size, Share, Trends and Forecast, 2026–2034

Market Overview

The global chemiluminescence immunoassay market is expanding as healthcare providers increasingly rely on sensitive and automated laboratory testing for disease detection and monitoring. Chemiluminescence immunoassay (CLIA) is a laboratory testing technique that uses light-emitting chemical reactions to detect and measure substances such as hormones, proteins, antibodies, and antigens in biological samples. Its high sensitivity, accuracy, and automation capabilities support its widespread use in clinical diagnostics.

Growing demand for diagnostic testing across infectious diseases, oncology, cardiology, endocrinology, and autoimmune disorders is supporting market development. Hospitals, clinics, and diagnostic laboratories use CLIA systems to improve testing efficiency and obtain reliable results for clinical decision-making. Technological developments in multiplex assays and AI-enabled analysis are also shaping the chemiluminescence immunoassay market.

Market Size and Forecast

The global chemiluminescence immunoassay market size was valued at USD 12.71 billion in 2025 and is projected to increase from USD 13.19 billion in 2026 to USD 17.75 billion by 2034. The market is expected to register a CAGR of 3.78% during the forecast period from 2026 to 2034.

North America dominated the global market in 2025, accounting for 39.2% of the total market share. Asia Pacific is projected to be the fastest-growing region, registering a CAGR of 8.94% through 2034. Increasing diagnostic testing requirements and the adoption of automated laboratory technologies are supporting the market's expansion across regions.

Market Drivers

Growing Demand for Clinical Diagnostic Testing

Increasing demand for accurate and timely disease detection is supporting the adoption of chemiluminescence immunoassay systems. These technologies enable laboratories to identify and measure biomarkers associated with infectious diseases, cardiovascular conditions, endocrine disorders, and other health conditions. Their high sensitivity and reliable analytical performance make them suitable for routine diagnostic applications.

Hospitals and diagnostic laboratories rely on immunoassay testing to support screening, diagnosis, and disease monitoring. The broad application of CLIA across clinical testing requirements is strengthening demand for instruments, reagents, and assay kits. This recurring need for diagnostic testing is supporting the growth of the chemiluminescence immunoassay market.

Expansion of Automated Laboratory Testing

The increasing use of laboratory automation is supporting the adoption of chemiluminescence immunoassay platforms. Automated analyzers help laboratories process diagnostic samples efficiently while supporting consistent testing workflows and result generation. Growing diagnostic volumes are encouraging healthcare facilities to adopt systems that improve laboratory productivity.

Software solutions and instrument connectivity are also becoming important components of automated diagnostic operations. These capabilities support workflow integration, data management, and result analysis. The growing emphasis on streamlined laboratory processes is contributing to demand for advanced CLIA systems.

Market Challenges

Dependence on Specialized Laboratory Infrastructure

Chemiluminescence immunoassay testing relies on dedicated instruments, assay reagents, and laboratory infrastructure. The need for specialized equipment and supporting operational resources can create adoption challenges for healthcare facilities with limited laboratory capabilities. Such requirements may restrict the deployment of advanced CLIA platforms in resource-constrained settings.

High Dependence on Consumable Supplies

CLIA systems require recurring supplies of reagents, assay kits, and other consumables to support routine testing. Continuous replacement requirements can increase operating expenses for diagnostic laboratories and healthcare facilities. Budget constraints may influence purchasing decisions and affect the adoption of these systems among smaller testing providers.

Market Opportunities

Growing Adoption of Saliva-Based Testing

Saliva is emerging as an important sample type in the chemiluminescence immunoassay market because of its non-invasive collection and convenient handling. The segment is projected to register the highest CAGR of 8.52% during 2026–2034. Increasing interest in patient-friendly diagnostic methods and biomarker detection is supporting its growth potential.

The adoption of saliva-based testing can expand the use of CLIA across diagnostic applications where convenient sample collection is important. This development creates opportunities for manufacturers to introduce assay solutions designed for saliva-based biomarker analysis.

Increasing Use in Pharmaceutical and Biotechnology Research

Pharmaceutical and biotechnology companies are expected to record the highest growth among end users, with a projected CAGR of 8.26% during the forecast period. Increasing use of immunoassays in drug discovery, clinical research, and biopharmaceutical development is supporting demand from this segment.

Growing investment in biologics and targeted therapies is also creating opportunities for specialized diagnostic and analytical testing solutions. Manufacturers offering reliable immunoassay platforms for research and development activities may benefit from this expanding application base.

Market Segmentation

The chemiluminescence immunoassay market is segmented by product, sample type, application, and end user.

By Product

The consumables segment dominated the market, accounting for 61.7% of the market share in 2025. Recurring demand for reagents, assay kits, and other testing materials supports its leading position across routine diagnostic applications. Meanwhile, software and services are projected to register the highest CAGR of 8.21%, supported by increasing adoption of laboratory automation, data management solutions, instrument connectivity, and result analysis tools.

By Sample Type

Blood accounted for the largest market share of 67.3% in 2025, reflecting its widespread use in clinical diagnostics and suitability for detecting biomarkers associated with infectious, cardiovascular, and endocrine diseases. Saliva is projected to be the fastest-growing segment, registering a CAGR of 8.52% from 2026 to 2034. Its non-invasive collection and convenient handling are supporting adoption.

By Application

Infectious disease represented the leading application segment, accounting for 24.5% of the market in 2025. The continued requirement for accurate pathogen detection, screening, and disease monitoring supports demand for immunoassay testing. Oncology is expected to record the highest CAGR of 8.41%, driven by increasing demand for early cancer detection, biomarker analysis, and treatment monitoring.

By End User

Hospitals and clinics dominated the market with a 43.6% share in 2025. High diagnostic testing volumes, established laboratory infrastructure, and the need for timely clinical results support this segment's leading position. Pharmaceutical and biotechnology companies are projected to grow at the highest CAGR of 8.26%, supported by increasing immunoassay applications in drug discovery, clinical research, and biopharmaceutical development.

Regional Analysis

North America

North America dominated the chemiluminescence immunoassay market, accounting for 39.2% of the global share in 2025. The region's demand is supported by diagnostic testing requirements and established laboratory services.

In the U.S., an ageing population is expected to contribute to increasing diagnostic testing needs. The U.S. Census Bureau projects that one in five Americans will be aged 65 or older by 2030. Continued demand for clinical laboratory services is also reflected in the projected 3% employment growth for clinical laboratory technologists and technicians between 2025 and 2035.

Canada is also expected to experience increasing demand for immunoassay-based diagnostics. Statistics Canada projects that the population aged 85 and older will increase from approximately 952,000 in 2025 to 3.3–4.2 million by 2075. This demographic development is expected to support demand for diagnostic and laboratory services.

Asia Pacific

Asia Pacific is projected to be the fastest-growing regional market, registering a CAGR of 8.94% from 2026 to 2034. Increasing diagnostic requirements and ageing populations across major countries are supporting the region's growth prospects.

Japan's ageing population is expected to increase demand for chronic disease monitoring and laboratory-based diagnostic testing. In China, the population aged 60 and older is projected to exceed 400 million by around 2035, potentially supporting wider access to immunoassay-based diagnostic services.

India is also expected to experience growing demand for diagnostic testing as its population aged 60 and older is projected to reach 230 million by 2036. The National Health Mission's diagnostic framework is supporting stronger laboratory infrastructure and wider access to essential diagnostic tests across public healthcare facilities.

Europe

Europe accounted for 27.4% of the chemiluminescence immunoassay market in 2025. Increasing diagnostic testing requirements and an ageing population are supporting regional demand.

In the U.K., the NHS conducts more than 1.5 billion diagnostic tests annually, with over 85% of clinical pathways involving diagnostic tests. Germany's ageing population is also expected to support demand, as the number of people aged 67 and older is projected to increase from 16.7 million in 2024 to 20.5–21.3 million by 2038.

Key Players

The chemiluminescence immunoassay market is moderately consolidated, with established in-vitro diagnostics companies, laboratory equipment manufacturers, reagent suppliers, and specialized diagnostic solution providers competing across the industry. The leading five companies are estimated to collectively account for approximately 40–45% of the global market share, although their exact combined share is not publicly disclosed.

Key players operating in the market include:

1. Thermo Fisher Scientific Inc. (U.S.)

2. PerkinElmer, Inc. (U.S.)

3. Abbott Laboratories (U.S.)

4. F. Hoffmann-La Roche Ltd. (Switzerland)

5. Beckman Coulter, Inc. (U.S.)

6. Siemens Healthcare Private Limited (India)

7. Eppendorf SE (Germany)

8. Sartorius AG (Germany)

Competition is primarily based on assay accuracy, analytical sensitivity, test menu breadth, instrument reliability, automation capabilities, regulatory approvals, and global distribution networks. Emerging players are focusing on innovative assay technologies, compact analyzers, cost-effective testing solutions, faster turnaround times, and specialized diagnostic panels.

Conclusion

The chemiluminescence immunoassay market is expected to experience steady growth through 2034, supported by increasing clinical diagnostic requirements and the adoption of automated laboratory testing. Consumables remain the leading product segment, while saliva-based testing and pharmaceutical and biotechnology applications present significant growth potential. North America continues to hold the largest regional share, whereas Asia Pacific is projected to record the fastest growth during the forecast period.

Technological developments in multiplex assays and AI-enabled immunoassay analysis are also shaping the market's competitive landscape. Manufacturers focusing on diagnostic accuracy, automation, specialized testing solutions, and laboratory workflow integration are positioned to address evolving market requirements.

 Report Link: http://straitsresearch.com/report/chemiluminescence-immunoassay-market